World Health Organization : Year 2002 ; Communicable Diseases and Emerging Infectious Diseases ; Department of Control, Prevention, And Eradication, Strategy Development and Monitoring for Eradication and Elimination, No. 2002.28: Annual Report on Lymphatic Filariasis

By Francesco Rio, Dr.

Book Id: WPLBN0000213737
Format Type: PDF eBook
File Size: 0.9 MB
Reproduction Date: 2005

Title:	World Health Organization : Year 2002 ; Communicable Diseases and Emerging Infectious Diseases ; Department of Control, Prevention, And Eradication, Strategy Development and Monitoring for Eradication and Elimination, No. 2002.28: Annual Report on Lymphatic Filariasis
Author:	Francesco Rio, Dr.
Volume:
Language:	English
Subject:	Health., Public health, Wellness programs
Collections:	Medical Library Collection, World Health Collection
Historic Publication Date:
Publisher:	World Health Organization


Citation APA MLA Chicago Dr, F. R. (n.d.). World Health Organization : Year 2002 ; Communicable Diseases and Emerging Infectious Diseases ; Department of Control, Prevention, And Eradication, Strategy Development and Monitoring for Eradication and Elimination, No. 2002.28. Retrieved from http://gutenberg.cc/

Description
Medical Reference Publication

Excerpt
In the countries A total of 26 million people in 22 countries were administered a 2-drug, once-yearly treatment in the second year of mass drug administration (MDA) in 2001, almost a ten-fold increase from the year 2000. Eleven countries, whose national plans and requests for donated drugs were reviewed and approved, will implement their national programmes in 2002. A total of 44 million albendazole tablets were shipped by GlaxoSmithKline to 26 countries for either the first or a subsequent round of mass drug administration. A total of 22 million ivermectin tablets (Mectizan®) were shipped by Merck & Co., Inc. to 8 countries covered by the African and Eastern Mediterranean Programme Review Groups; 15.5 million were for MDA in areas with only lymphatic filariasis (LF) while 6.5 million were for areas where lymphatic filariasis and onchocerciasis are co-endemic. Surveys continued in all the regions to map implementation units with LF transmission.

Table of Contents
CONTENTS Programme Highlights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Chapter 1. Understanding the problem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 The disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Transmission of lymphatic filariasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Clinical forms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Global burden . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 WHO’s global strategy to eliminate lymphatic filariasis . . . . . . . . . . . . . . . . . . . . . . 9 Finding the answers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Chapter 2. Supporting the Global Initiative . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 The start of the global initiative . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 The Global Alliance to Eliminate Lymphatic Filariasis . . . . . . . . . . . . . . . . . . . . . . . 11 The regionalization process . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 1. African Programme Review Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 2. American Programme Review Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 3. Eastern Mediterranean Programme Review Group . . . . . . . . . . . . . . . . . . . . . . 17 4. Mekong-Plus Programme Review Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 5. Indian Subcontinent Programme Review Group . . . . . . . . . . . . . . . . . . . . . . . . 18 6. PacELF Coordination and Review Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Chapter 3. Implementing the programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Initial assessment and mapping of LF distribution . . . . . . . . . . . . . . . . . . . . . . . . . 19 Mass drug administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Social mobilization and advocacy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Preventing and limiting disability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Training . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 Monitoring PELF and information system . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 Activities in regions and countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 1. African Programme Review Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34 2. American Programme Review Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 3. Eastern Mediterranean Programme Review Group . . . . . . . . . . . . . . . . . . . . . . 40 4. Mekong-Plus Programme Review Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 5. Indian Subcontinent Programme Review Group . . . . . . . . . . . . . . . . . . . . . . . . 43 6. PacELF Coordination and Review Group . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45